Market research
0IL.F IntelGenx Technologies Corp
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 2.6
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US45822R1014
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 2.6
About
About IntelGenx Technologies Corp
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0IL.F discussion.
5 years, 5 months ago
IntelGenx Technologies Corp is currently in a long term uptrend where the price is trading 35.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.1.
IntelGenx Technologies Corp's total revenue rose by 1061.8% to $790K since the same quarter in the previous year.
Its net income has increased by 52.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 76.0% to $-533K since the same quarter in the previous year.
Based on the above factors, IntelGenx Technologies Corp gets an overall score of 5/5.